期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.801269
关键词
Circulating tumour cells; cell-free DNA; circulating tumour DNA; microRNA and exosomes; lung cancer; liquid biopsy
类别
资金
- NHMRC [1157741]
- Cure Cancer [1182179]
- PA Research Foundation
- National Health and Medical Research Council of Australia [1157741] Funding Source: NHMRC
Liquid biopsies have emerged as a non-invasive diagnostic approach for screening, early diagnosis, and prognostication of lung cancer patients.
Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early diagnosis is crucial for the management and treatment of this disease. Non-invasive means of determining tumour information is an appealing diagnostic approach for lung cancers as often accessing and removing tumour tissue can be a limiting factor. In recent years, liquid biopsies have been developed to explore potential circulating tumour biomarkers which are considered reliable surrogates for understanding tumour biology in a non-invasive manner. Most common components assessed in liquid biopsy include circulating tumour cells (CTCs), cell-free DNA (cfDNA), circulating tumour DNA (ctDNA), microRNA and exosomes. This review explores the clinical use of circulating tumour biomarkers found in liquid biopsy for screening, early diagnosis and prognostication of lung cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据